---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019835"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T17:43:53.456969+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS Q1 net loss $5.5M; BREXAFEMME sales $0.7M; CANDLE study positive for rVVC

## Summary
- Net loss $5.5M ($0.17/share) vs $4.7M ($0.18) in Q1 2021; product revenue $0.7M from BREXAFEMME.
- Cash $95.2M at March 31; plus $42M net from April offering; runway into Q1 2024.
- BREXAFEMME: ~4,000 prescriptions Q1, 1,800 HCPs; 55% commercial coverage (93M lives).
- CANDLE Phase 3 met endpoint: 65.4% vs 53.1% placebo (p=0.02) for rVVC prevention; sNDA planned Q2 2022.
- MARIO global Phase 3 initiated for invasive candidiasis; first patient enrollment expected Q2 2022.

## SEC filing metadata
- accession: 0001564590-22-019835
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000156459022019835/0001564590-22-019835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000156459022019835/scyx-8k_20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019835
- JSON: https://secwatch.observer/filing/0001564590-22-019835.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.